Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7284755 alone or with atezolizumab in advanced or metastatic solid tumors
NL-OMON55111Phase 1Recruiting
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Nonhematologic neoplasms comparing RO7284755 monotherapy with RO7284755 plus atezolizumab (2 arms). Primary endpoints: Safety and tolerability of RO7284755 alone or with atezolizumab, Maximum tolerated dose and/or recommended dose for extension and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
eciskafusp alfaatezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON55111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55111.